BRAI

Brain+ CPSE:BRAINP Stock Report

Last Price

kr.2.58

Market Cap

kr.30.5m

7D

7.5%

1Y

n/a

Updated

20 May, 2022

Data

Company Financials
BRAINP fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

BRAINP Stock Overview

Brain+ A/S develops digital therapeutics for Alzheimer’s and dementia.

Brain+ Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Brain+
Historical stock prices
Current Share Pricekr.2.58
52 Week Highkr.5.10
52 Week Lowkr.2.02
Beta0
1 Month Change1.58%
3 Month Change-11.03%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-41.36%

Recent News & Updates

Shareholder Returns

BRAINPDK Healthcare ServicesDK Market
7D7.5%3.3%3.5%
1Yn/a-19.9%2.3%

Return vs Industry: Insufficient data to determine how BRAINP performed against the Danish Healthcare Services industry.

Return vs Market: Insufficient data to determine how BRAINP performed against the Danish Market.

Price Volatility

Is BRAINP's price volatile compared to industry and market?
BRAINP volatility
BRAINP Average Weekly Movement14.0%
Healthcare Services Industry Average Movement7.5%
Market Average Movement6.5%
10% most volatile stocks in DK Market10.8%
10% least volatile stocks in DK Market3.9%

Stable Share Price: BRAINP is more volatile than 90% of Danish stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: BRAINP's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Danish stocks.

About the Company

FoundedEmployeesCEOWebsite
2012n/aKim Baden-Kristensenhttps://www.brain-plus.com

Brain+ A/S develops digital therapeutics for Alzheimer’s and dementia. The company develops cognitive stimulation therapy (CST), a therapy that treats the main symptoms of dementia; Computerized Cognitive Training, a cognitive training method for patients with mild cognitive impairment; and Starry Night, memory test for early detection and monitoring of Alzheimer’s. In addition, it develops an interface for clinicians to track and trace the patient’s treatment progress.

Brain+ Fundamentals Summary

How do Brain+'s earnings and revenue compare to its market cap?
BRAINP fundamental statistics
Market Capkr.30.49m
Earnings (TTM)-kr.7.08m
Revenue (TTM)kr.3.99m

7.6x

P/S Ratio

-4.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BRAINP income statement (TTM)
Revenuekr.3.99m
Cost of Revenuekr.0
Gross Profitkr.3.99m
Other Expenseskr.11.07m
Earnings-kr.7.08m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.60
Gross Margin100.00%
Net Profit Margin-177.34%
Debt/Equity Ratio0%

How did BRAINP perform over the long term?

See historical performance and comparison

Valuation

Is Brain+ undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


1.48x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BRAINP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BRAINP's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: BRAINP is unprofitable, so we can't compare its PE Ratio to the European Healthcare Services industry average.

PE vs Market: BRAINP is unprofitable, so we can't compare its PE Ratio to the Danish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BRAINP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BRAINP is good value based on its PB Ratio (1.5x) compared to the XE Healthcare Services industry average (2.7x).


Future Growth

How is Brain+ forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


22.2%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Brain+ has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Brain+ performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-55.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BRAINP is currently unprofitable.

Growing Profit Margin: BRAINP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BRAINP is unprofitable, and losses have increased over the past 5 years at a rate of 55% per year.

Accelerating Growth: Unable to compare BRAINP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BRAINP is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-3%).


Return on Equity

High ROE: BRAINP has a negative Return on Equity (-34.36%), as it is currently unprofitable.


Financial Health

How is Brain+'s financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BRAINP's short term assets (DKK13.3M) do not cover its short term liabilities (DKK24.5M).

Long Term Liabilities: BRAINP's short term assets (DKK13.3M) exceed its long term liabilities (DKK1.8M).


Debt to Equity History and Analysis

Debt Level: BRAINP has more cash than its total debt.

Reducing Debt: Insufficient data to determine if BRAINP's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BRAINP has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BRAINP has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 200.1% each year.


Dividend

What is Brain+ current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BRAINP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BRAINP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BRAINP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BRAINP's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BRAINP has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Kim Baden-Kristensen

no data

Tenure

Mr. Kim Baden-Kristensen is Founder, Chief Executive Officer and Managing Director of Brain+ ApS. He is Co-Founder and Chief Executive Officer of Brain+ A/S. He began his career in high tier strategic mana...


Leadership Team

Experienced Management: BRAINP's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: BRAINP's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: BRAINP only recently listed within the past 12 months.


Top Shareholders

Company Information

Brain+ A/S's employee growth, exchange listings and data sources


Key Information

  • Name: Brain+ A/S
  • Ticker: BRAINP
  • Exchange: CPSE
  • Founded: 2012
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Implied Market Cap: kr.30.485m
  • Shares outstanding: 11.82m
  • Website: https://www.brain-plus.com

Number of Employees


Location

  • Brain+ A/S
  • KOebmagergade 53
  • 3rd floor
  • Copenhagen
  • Capital Region of Denmark
  • 1150
  • Denmark

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/20 00:00
End of Day Share Price2022/05/20 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.